| abstract |
Kind Code: A1 The present invention relates to the adjustment and deficiency of a chondroitinase protein variant, its use in a method for promoting the diffusion of therapeutic components into tissues, its use for central nervous system ("CNS") disorders or neurological function recovery after disease. provide. Chondroitinase ABC type I, chondroitinase ABC type II, chondroitinase AC, chondroitinase B deficiency, substitution mutant or fusion protein. Also, a therapeutic composition comprising each of the other mammalian enzyme variants, hyaluronidase 1, hyaluronidase 2, hyaluronidase 3, hyaluronidase 4, and optionally an enzyme such as PH-20, independently. [Selection] Figure 7 |